Medicines360 Appoints Andrea Olariu, MD, PhD as Chief Executive Officer

Dr. Olariu brings depth of expertise in Clinical, Medical and Regulatory Affairs, and Product Development SAN FRANCISCO – May [30] – Medicines360, a mission-driven nonprofit women’s health pharmaceutical organization, announced today that its Board of Directors has named Andrea Olariu, MD, PhD as Chief Executive Officer, effective immediately. Dr. Olariu served most recently as Chief […]
More Bumps in Reproductive Healthcare Access

At M360, we believe that all women should have control over their reproductive healthcare, including abortion and contraception. Since the Supreme Court’s decision in Dobbs v. Jackson Women’s Health Organization in June of last year, the reproductive health policy landscape has changed profoundly. Women today face drastic new barriers to accessing the full range of […]
Reduced Drug Pricing Within View and More Good Policy News

At Medicines360, our work is focused on addressing gaps women face in accessing the medicines they need. While that means we pursue drug research and development, as a mission-driven organization, it also demands that we pay attention to and speak up about policies that negatively impact the health and well-being of women we serve. In […]
Supreme Court’s Decision in Mifepristone Case Protects Women and Science, For Now

San Francisco, CA – Last week, the United States Supreme Court granted a stay of execution, requested by the Department of Justice (DOJ) and Danco Laboratories, in Alliance for Hippocratic Medicine et al v. U.S. Food and Drug Administration et al. This stay allows mifepristone – one of two drugs used in medication abortion – […]
Medicines360 Stands with Women in Wake of Texas Mifepristone Case

San Francisco, CA – Today, following the recent federal court decision in Texas designed to pull Mifepristone from the U.S. market, Medicines360 CEO Tina Raine-Bennett, MD, MPH, released the following statement: “Last week, a lone federal judge in Texas declared in Alliance for Hippocratic Medicine et al v. U.S. Food and Drug Administration et al […]
2021-2022 Daniel R. Mishell, Jr, MD Outstanding Article Award Presented to Tina Raine-Bennett, MD, MPH, FACOG

Medicines360 Chief Executive Officer, Tina Raine-Bennett, MD, MPH, FACOG, was recently awarded the 2021-2022 Daniel R. Mishell, Jr, MD Outstanding Article Award for her original research article entitled, “Ectopic pregnancy prevention: Further evidence of benefits of prescription contraceptives.” Dr. Raine-Bennett’s study explored the incidence of ectopic pregnancy in the last decade in U.S. women who […]
Looking Back at 2022 & Moving Forward into 2023

Dear Friends of Medicines360 – Happy New Year! 2023 is already off to a roaring start and Medicines360 is excited to share the inaugural edition of “All Access,” our newly launched bulletin. With drug prices in the U.S. continuing to rise, breakthrough products and essential medications have become even more unaffordable, particularly for people without health insurance. As […]
Victories and Reflections on Medicines360 Policy Work in 2022

Nearly three years into the pandemic, it is impossible to ignore that the health care policy environment has been forever changed — and that change continues. The pandemic laid bare long-standing inequities in access for people of color, people with low incomes, LGBTQ+ people, women, and people who live at the intersections of these identities. […]
Medicines360 Applauds U.S. Congress for Enshrining Nonprofit Pharma in Federal Law for the First Time

The Omnibus Legislation Passed Last Week Includes Provisions to Conduct a GAO Report on Nonprofit Pharma and include Nonprofit Pharma in an HHS Domestic Manufacturing Study January 4, 2023 San Francisco, CA – Last week, Congress passed bipartisan legislation to fund the Federal Government for the remainder of Fiscal Year 2023 and to ensure other […]
FDA Approves Medicines360’s LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Eight Years

FDA Approval of Extended Duration of Use Supports Medicines360’s Mission to Expand Women’s Access Nov. 14, 2022 SAN FRANCISCO – Medicines360, a global nonprofit organization with a mission to expand women’s access to quality medicines, announced today that the U.S. Food and Drug Administration (FDA) has approved Medicines360’s Supplemental New Drug Application (sNDA) to extend […]